AtheroGenics Financial Statements
AtheroGenics Financial Information
| Company Type | Public |
|---|---|
| Fiscal Year-End | December |
© 2009 Morningstar, Inc. Financial Data provided by
AtheroGenics Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.0 | 52.3 | 31.7 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | -- | -- | -- |
| Total Net Income ($ mil.) | (64.2) | (49.5) | (67.3) |
| Diluted EPS (Net Income) | (1.62) | (1.25) | (1.71) |
AtheroGenics Quarterly Statements
| Quarter Ending Mar 09 | Quarter Ending Dec 08 | Quarter Ending Sep 08 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.0 | 0.0 | 0.0 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | -- | -- | -- |
| Total Net Income ($ mil.) | (4.6) | (5.1) | (29.8) |
| Diluted EPS (Net Income) | (0.12) | (0.13) | (0.75) |
AtheroGenics Stock Quote & Chart
•
•
--
•
•
%
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
AtheroGenics Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 0.11 | 16.45 | 7.01 |
| Price/Earnings Ratio | (0.02) | 384.62 | 25.51 |
| Price/Book Ratio | (0.01) | 3.53 | 6.74 |
| Price/Cash Flow Ratio | (0.03) | 80.00 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed AtheroGenics Financial Ratios
AtheroGenics Competitive Intelligence
| Eli Lilly | GlaxoSmithKline | Merck | |
|---|---|---|---|
| Annual Sales ($ mil.) | 20,378.0 | 35,244.6 | 18,502.0 |
| Employees | 40,500 | 99,003 | 51,000 |
| Market Cap ($ mil.) | 39,560.8 | 114,528.4 | 46,142.1 |
Competitive Landscape
